Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock Rating Reaffirmed by HC Wainwright

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $50.00 price target on the biotechnology company’s stock.

ATNM has been the topic of several other reports. StockNews.com lowered shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, March 19th. B. Riley decreased their target price on shares of Actinium Pharmaceuticals from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday, December 11th. Finally, Maxim Group boosted their target price on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, Actinium Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $26.92.

Actinium Pharmaceuticals Stock Performance

NYSEAMERICAN:ATNM opened at $7.94 on Tuesday. Actinium Pharmaceuticals has a 1-year low of $4.00 and a 1-year high of $9.86. The firm has a market capitalization of $220.41 million, a P/E ratio of -4.14 and a beta of 0.01.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ATNM. BlackRock Inc. increased its stake in shares of Actinium Pharmaceuticals by 1.1% during the 1st quarter. BlackRock Inc. now owns 230,950 shares of the biotechnology company’s stock valued at $1,180,000 after acquiring an additional 2,618 shares during the last quarter. Blair William & Co. IL increased its stake in shares of Actinium Pharmaceuticals by 15.8% during the 1st quarter. Blair William & Co. IL now owns 100,566 shares of the biotechnology company’s stock valued at $514,000 after acquiring an additional 13,700 shares during the last quarter. State Street Corp increased its stake in shares of Actinium Pharmaceuticals by 12.5% during the 1st quarter. State Street Corp now owns 63,015 shares of the biotechnology company’s stock valued at $322,000 after acquiring an additional 7,023 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Actinium Pharmaceuticals during the 2nd quarter valued at about $278,000. Finally, Millennium Management LLC acquired a new position in shares of Actinium Pharmaceuticals during the 2nd quarter valued at about $159,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.